US3061510A - Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule - Google Patents
Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule Download PDFInfo
- Publication number
- US3061510A US3061510A US752398A US75239858A US3061510A US 3061510 A US3061510 A US 3061510A US 752398 A US752398 A US 752398A US 75239858 A US75239858 A US 75239858A US 3061510 A US3061510 A US 3061510A
- Authority
- US
- United States
- Prior art keywords
- radioactive
- fatty
- wax
- capsule
- iodinated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000463 material Substances 0.000 title claims description 42
- 230000002285 radioactive effect Effects 0.000 title claims description 28
- 239000002775 capsule Substances 0.000 title claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 235000021313 oleic acid Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 150000002889 oleic acids Chemical class 0.000 description 4
- 239000012217 radiopharmaceutical Substances 0.000 description 4
- 229940121896 radiopharmaceutical Drugs 0.000 description 4
- 230000002799 radiopharmaceutical effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 239000012178 vegetable wax Substances 0.000 description 3
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004203 pancreatic function Effects 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- -1 triolein Chemical class 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012168 ouricury wax Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1262—Capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
RADIOACTIVE IQDINATED (I FATTY MATE- RIAL ADMIXED WITH WAX-LIKE MATERIAL IN CAPSULE Paul Numerof, Highland Park, N.J., and Joseph Knoll,
Springfield Gardens, N.Y., assignors to Olin Mathieso n Chemical Corporation, New York, N.Y., a corporation of Virginia N Drawing. Filed Aug. 1, 1958, Ser. No. 752,398
10 Claims. (Cl. 167-51) This invention relates to radioactive pharmaceutical preparations and, more particularly, to stable preparations of radioactive fatty materials for diagnostic purposes.
It is frequently desirable that means be provided for tracing the course of aparticular medicament or diagnostic agent in the system of the patient undergoing treatment. One technique which has been employed widely in the last several years makes use of the properties of radioactive substances in order to achieve this objective. In particular, radioactive fatty materials have been employed in order to faciltate the study of pancreatic function and gastrointestinal absorption. However, the liquid radiopharmaceutical preparations heretofore available have suffered from certain disadvantages, primarily from difliculties in handling and in administration inherent in the use of a liquid preparation. There is, therefore, a continued demand for the development of radio-active pharmaceutical preparations in a form which is easier to standardize and handle and which is simpler to administer.
It is an object of the present invention to provide readily administrable radiopharmaceutical preparations.
It is a more particular object of this invention to provide readily administrable preparations of radioactive fatty materials.
Other objects of this invention will in part be obvious and will in part appear hereinafter.
It has been found that the above and other objects can be achieved by the provision of the noval formulations of the present invention, which are radiopharmaceutical preparations comprising an intimate admixture of a radioactive-iodinated, normally liquid fatty material and a waxlike material having a softening point at least above room temperature. The preparations are preferably contained in an encapsuling substance of the type conventionally employed in capsules. The term fatty material as employed herein includes fatty acids and fats.
The compositions of the present invention afford a product containing the radioactive fatty material in a form which is easier and simpler to standardize and to handle than heretofore available. More particularly, the products of the present invention contain the radioactive fatty materials in a form which provides for far greater ease of administration and also of calibration. It has been found that the radio-pharmaceutical preparations of the present invention are easier for the physician to handle and to administer. In addition, it has been found that loss of radioactivity and leakage of the carrier from the container are both prevented by the present invention.
The radioactive fatty material employed in the compositions of the present invention can be any one of the radioactive fats and fatty acids now employed in therapeutic or diagnostic applications. More particularly, these radioactive fatty materials are liquids which are derived from unsaturated fatty substances which are capable of combining with molecular iodine to form iodinated fats. Representative of such unsaturated fatty materials are glycerides of unsaturated fatty acids, such as triolein, the triglyceride of oleic acid, and unsaturated fatty acids containing one or more unsaturated carbon to carbon linkages in the fatty acid chains. Specific examples of such 3,061,510 Patented Oct. 30, 1962 fatty acids are oleic, linoleic, linolenic, and arachidonic acids.
The preparation of iodinated fatty materials containing radioactive I is well known. However, for the sake of completeness, reference is here made to the article by J. R. Malin, in Proceedings of Society for Experimental Biology and Medicine (1956), volume 92, page 471, wherein the preparations of such substances is described.
The normally solid wax-like material employed in preparing the products of the present invention can be any digestible, non-toxic material which has a softening point above room temperature. It can be selected from glycerides and other fatty acid esters, fatty acids, or vegetable Waxes which have a softening point above room temperature. Among such materials there may be mentioned hydrogenated fats and oils such as cocoanut oil, cottonseed oil, and soybean oil; saturated fatty acids suchas stearic acid, palmitic acid, and lauric acid; and vegetable waxes such as carnauba wax and ouricury wax. The normally solid wax-like material may amount to from about 50% to about 99.9% of the fat composition. Preferably, however, it will comprise about 70% of the combined weights of the radioactive fatty material and the carrier.
The preparations of this invention are preferably contained in capsules of encapsulating material which may be any substance commonly employed in the art for this purpose. In general, it has been found that gelatin capsules are the most suitable for use in the present invention.
The novel products of the present invention are readily prepared by melting the normally solid wax-like material and admixing therewith the normally liquid radioactive fatty material. Thereafter, the liquid mixture which is formed is metered into a capsule and allowed to solidify. The particular order of addition of molten wax-like material to normally liquid radioactive fatty material is not critical and either one may be admixed with the other ingredient. The capsules are preferably prepared to contain on the order of about 0.001 to about 0.200 gram of radioactive fatty material.
While in general, as stated heretofore, the normally solid Wax-like material may comprise from about 50% to about 99.9% of the total weight, it has been found that where an iodinated oleic acid is employed as the radioactive fatty material the percentage of oleic acid in the total composition should preferably not exceed 35%. If proportions of oleic acid in excess of 35% are employed it has been found that leakage of the material from the gelatin capsules will occur.
For a fuller understanding of the present invention reference is made to the following examples, which are for illustration only and are not to be construed as limiting the scope of the present invention.
Example I Three parts of hydrogenated cottonseed oil is heated to about C. and to the molten fat there is then added one part of radioactive (I iodinated oleic acid. The molten mixture is then metered into gelatin capsules and allowed to solidify. solidification of the melt occurs at 30 C. The capsules are then closed and stored in contact with the atmosphere at ambient temperature. The capsules proved stable for periods in excess of one month.
Example II The procedure of Example I is repeated using radioactive, iodinated material derived from triolein in place of the oleic acid employed in Example I. Similar satisfactory results were obtained.
The preparations of the foregoing examples are particularly designed for the clinical evaluation of gastrointestinal absorption of fats and pancreatic function, and
for this purpose are administered at dosage levels of about 10 to 100 microcuries.
The invention may be variously otherwise embodied within the scope of the appended claims.
What is claimed is:
1. A pharmaceutical preparation comprising a twopiece capsule containing an intimate admixture of from about 50% to about 99.9% of a digestible, non-toxic wax-like material having a softening point at least above room temperature, and from about 0.1% to about 50% of a normally liquid radioactive iodinated (1 fatty material.
2. The pharmaceutical preparation of claim 1 in which the wax-like material is a saturated fatty acid.
3. The pharmaceutical preparation of claim 1 in which the wax-like material is a vegetable wax.
4. The pharmaceutical preparation of claim 1 in which the radioactive fatty material is radioactive (I iodinated triolein.
5. The pharmaceutical preparation of claim 1 in which 20 the wax-like material is a hydrogenated glyceride oil.
6. The pharmaceutical preparation of claim 5 in which 'the wax-like material is a hydrogenated cottonseed oil.
7. The pharmaceutical preparation of claim 1 in which the radioactive fatty material is derived from an unsaturated fatty acid.
8. The pharmaceutical preparation of claim 7 in which the radioactive fatty material is radioactive (I iodinated oleic acid.
9. A pharmaceutical preparation comprising a twopiece capsule containing an intimate admixture of from about 65% to about 99.9% by weight of hydrogenated cottonseed oil and from about to about 0.1% of radioactive (I iodinated oleic acid.
10. The composition of claim 9 in which the capsule is a gelatin capsule.
References Cited in the file of this patent UNITED STATES PATENTS 2,298,122 Hailer Oct; 6, 1942 2,487,336 Hinds Nov. 8, 1949 2,566,200 Hicky Aug. 28, 1951 2,719,103 Jurist Sept. 27, 1955 2,844,512 Eble July 22, 1958 2,911,338 Tabern Nov. 3, 1959 OTHER REFERENCES Scope Weekly, June 6, 1956, p. 11. JAPhA, Practical Pharmacy Edition, August 1956, p. 539.
Claims (1)
1. A PHARMACEUTICAL PREPARATION COMPRISING A TWOPIECE CAPSULE CONTAINING AN INTIMATE ADMIXTURE OF FROM ABOUT 50% TO ABOUT 99.9% OF A DIGESTIBLE, NON-TOXIC WAX-LIKE MATERIAL HAVING A SOFTENING POINT AT LEAST ABOVE ROOM TEMPERATURE, AND FROM ABOUT 0.1% TO ABOUT 50% OF A NORMALLY LIQUID RADIOACTIVE IODINATED (I131) FATTY MATERIAL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US752398A US3061510A (en) | 1958-08-01 | 1958-08-01 | Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US752398A US3061510A (en) | 1958-08-01 | 1958-08-01 | Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3061510A true US3061510A (en) | 1962-10-30 |
Family
ID=25026150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US752398A Expired - Lifetime US3061510A (en) | 1958-08-01 | 1958-08-01 | Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3061510A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3121041A (en) * | 1960-07-20 | 1964-02-11 | Olin Mathieson | Capsule containing a pharmaceutically useful radioactive material |
| US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
| US3421282A (en) * | 1963-09-28 | 1969-01-14 | Daiichi Kagaku Yakuhin Co Ltd | Method for obtaining capsules having oily drugs closed therein |
| US3663685A (en) * | 1968-04-01 | 1972-05-16 | Minnesota Mining & Mfg | Biodegradable radioactive particles |
| US3670065A (en) * | 1968-06-19 | 1972-06-13 | Karl Gunnar Eriksson | Process for producing dosage units of a type resembling tablets |
| US3716631A (en) * | 1968-02-23 | 1973-02-13 | Philips Corp | Use of radioactive compounds to determine fat absorption |
| US3718737A (en) * | 1967-10-20 | 1973-02-27 | H Penn | Process of treating bile and novel iodine-131 complex |
| US4065552A (en) * | 1975-05-05 | 1977-12-27 | Giovanni Giacomo Costa | Method of detecting malignant neoplasms |
| US4473544A (en) * | 1979-11-24 | 1984-09-25 | Machulla Hans Juergen | Radio-iodine-labelled omega phenyl fatty acids |
| US4505888A (en) * | 1983-05-27 | 1985-03-19 | E. I. Du Pont De Nemours & Company | Tracer for circulation determinations |
| US4663149A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising inner and outer walls functioning as cooperative unit |
| US4663148A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising telescopically engaging members |
| US4692326A (en) * | 1984-03-21 | 1987-09-08 | Alza Corporation | Dispenser comprising inner positioned soft or hard capsule |
| US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
| DK151931B (en) * | 1977-11-03 | 1988-01-18 | Hoechst Ag | PROCEDURE FOR THE PREPARATION OF A PHARMACENTAL PREPARATION UNIT |
| FR2613933A1 (en) * | 1987-04-17 | 1988-10-21 | Biogal Gyogyszergyar | PROCESS FOR THE PREPARATION OF HIGH STABILITY SOFT GELATIN CAPSULES |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2298122A (en) * | 1941-01-27 | 1942-10-06 | United Drug Company | Digitalis capsule |
| US2487336A (en) * | 1946-02-25 | 1949-11-08 | William E Hinds | Penicillin product |
| US2566200A (en) * | 1947-06-07 | 1951-08-28 | Commercial Solvents Corp | Oral therapeutic tablets |
| US2719103A (en) * | 1947-12-19 | 1955-09-27 | Olin Mathieson | D-tubo-curarine chloride in suspension of water-insoluble soap in injectable oil |
| US2844512A (en) * | 1954-11-05 | 1958-07-22 | Upjohn Co | Fumagillin enveloped in fatty or waxy substance and enclosed in ultraviolet opaque container |
| US2911338A (en) * | 1954-03-09 | 1959-11-03 | Abbott Lab | Capsules and method of producing |
-
1958
- 1958-08-01 US US752398A patent/US3061510A/en not_active Expired - Lifetime
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2298122A (en) * | 1941-01-27 | 1942-10-06 | United Drug Company | Digitalis capsule |
| US2487336A (en) * | 1946-02-25 | 1949-11-08 | William E Hinds | Penicillin product |
| US2566200A (en) * | 1947-06-07 | 1951-08-28 | Commercial Solvents Corp | Oral therapeutic tablets |
| US2719103A (en) * | 1947-12-19 | 1955-09-27 | Olin Mathieson | D-tubo-curarine chloride in suspension of water-insoluble soap in injectable oil |
| US2911338A (en) * | 1954-03-09 | 1959-11-03 | Abbott Lab | Capsules and method of producing |
| US2844512A (en) * | 1954-11-05 | 1958-07-22 | Upjohn Co | Fumagillin enveloped in fatty or waxy substance and enclosed in ultraviolet opaque container |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3121041A (en) * | 1960-07-20 | 1964-02-11 | Olin Mathieson | Capsule containing a pharmaceutically useful radioactive material |
| US3421282A (en) * | 1963-09-28 | 1969-01-14 | Daiichi Kagaku Yakuhin Co Ltd | Method for obtaining capsules having oily drugs closed therein |
| US3374146A (en) * | 1966-04-18 | 1968-03-19 | American Cyanamid Co | Sustained release encapsulation |
| US3718737A (en) * | 1967-10-20 | 1973-02-27 | H Penn | Process of treating bile and novel iodine-131 complex |
| US3716631A (en) * | 1968-02-23 | 1973-02-13 | Philips Corp | Use of radioactive compounds to determine fat absorption |
| US3663685A (en) * | 1968-04-01 | 1972-05-16 | Minnesota Mining & Mfg | Biodegradable radioactive particles |
| USRE29066E (en) * | 1968-04-01 | 1976-12-07 | Minnesota Mining And Manufacturing Company | Biodegradable radioactive particles |
| US3670065A (en) * | 1968-06-19 | 1972-06-13 | Karl Gunnar Eriksson | Process for producing dosage units of a type resembling tablets |
| US4065552A (en) * | 1975-05-05 | 1977-12-27 | Giovanni Giacomo Costa | Method of detecting malignant neoplasms |
| DK151931B (en) * | 1977-11-03 | 1988-01-18 | Hoechst Ag | PROCEDURE FOR THE PREPARATION OF A PHARMACENTAL PREPARATION UNIT |
| US4473544A (en) * | 1979-11-24 | 1984-09-25 | Machulla Hans Juergen | Radio-iodine-labelled omega phenyl fatty acids |
| US4505888A (en) * | 1983-05-27 | 1985-03-19 | E. I. Du Pont De Nemours & Company | Tracer for circulation determinations |
| US4663149A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising inner and outer walls functioning as cooperative unit |
| US4663148A (en) * | 1984-03-21 | 1987-05-05 | Alza Corporation | Dispenser comprising telescopically engaging members |
| US4692326A (en) * | 1984-03-21 | 1987-09-08 | Alza Corporation | Dispenser comprising inner positioned soft or hard capsule |
| US4716031A (en) * | 1984-03-21 | 1987-12-29 | Alza Corporation | Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug |
| FR2613933A1 (en) * | 1987-04-17 | 1988-10-21 | Biogal Gyogyszergyar | PROCESS FOR THE PREPARATION OF HIGH STABILITY SOFT GELATIN CAPSULES |
| BE1000735A5 (en) * | 1987-04-17 | 1989-03-21 | Biogal Gyogyszergyar | PROCESS FOR THE PREPARATION OF SOFT GELATIN CAPSULES WITH HIGH STABILITY. |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3061510A (en) | Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule | |
| US3159545A (en) | Radioactive capsules | |
| US5140021A (en) | Method and dosage form for treatment of premenstrual syndrome | |
| US3344029A (en) | Sustained release composition | |
| US5738871A (en) | Pharmaceutical formulations | |
| US4888239A (en) | Ethanol fill formulation for sofgels etc. | |
| CA1092025A (en) | Pharmaceutical preparation adapted for oral administration | |
| GB1030127A (en) | Improvements in or relating to method of preparing sustained release pharmaceutical pellets and product thereof | |
| US4963540A (en) | Method for treatment of premenstrual syndrome | |
| US2924528A (en) | Synthetic hard butter | |
| US2776924A (en) | Composition of matter containing polyvinylpyrrolidone and a fatty carrier | |
| CN106256345A (en) | Vitamin C delivery system and liposome composition thereof | |
| US2988484A (en) | Alcohol soluble pharmaceutical compositions | |
| US3331742A (en) | Sterile mono- and di-glyceride pharmaceutical vehicle product for water and/or oil-soluble therapeutic substances | |
| US4761407A (en) | Solid galenical form for oral administration, and the process for its preparation | |
| NL194663B (en) | Process for the preparation of a highly stable soft gelatin capsule for therapeutic purposes. | |
| CA1135623A (en) | Thixotropic filling medium for hard gelatin capsules | |
| US3450821A (en) | Stable compositions containing eicosatetrayn - (5,8,11,14) - oic-(1) acid and derivatives thereof | |
| EP0276116A2 (en) | Capsule filling | |
| JPS634524B2 (en) | ||
| US2895881A (en) | Quinidine gluconate sustained medication tablet | |
| JP2795351B2 (en) | Aerosol composition for human body | |
| JPH05238954A (en) | Carrier suitable for chewing administration | |
| JP2506048B2 (en) | Capsule-containing bath agent composition | |
| EP3257502A1 (en) | Formulations in the form of capsules for oral systemic administration comprising s-adenosylmethionine and polyunsaturated fatty acids, preparation and use thereof |